Atlas Trials

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

11 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

RecordFirmDate
Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma (NCT06583083)Sun Yat-sen University2024-10-22
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma (NCT06376721)Beijing Tongren Hospital2024-04-14
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (NCT06314334)Fudan University2024-03-04
Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma (NCT05058755)Xinhua Hospital, Shanghai Jiao Tong University School of Medicine2021-09-17
Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL (NCT04366128)Rong Tao2020-04-25
Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma (NCT04004572)Rong Tao2019-07-01
Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma (NCT03936452)Sun Yat-sen University2019-04-28
Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma (NCT03630731)Chinese Academy of Medical Sciences2018-08-01
Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma (NCT03618238)Xinhua Hospital, Shanghai Jiao Tong University School of Medicine2018-07-25
SIMPLE Chemotherapy for NK Lymphoma/Leukaemia (NCT03623087)The University of Hong Kong2017-07-01
Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma (NCT03107962)Mingzhi Zhang2017-02-19

Track Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type automatically

Every clearance here is in the API, with alerts when new ones post.